\
&
Contact us
\
&
Contact us
Published on | 1 month ago
ProgrammesThe course " Generating Business from Research" is addressed to researchers, innovation managers, technology transfer professionals, and potential participants interested in EIC Transition and in the exploitation of research results through spin‑offs.
Having a promising research result does not necessarily mean that it can, or should, be transformed into a viable business. The objective of this course is to equip learners with a clear and practical framework to assess when launching a business makes sense and, equally importantly, when it does not.
The framework is built around three cascading questions:
These questions are explored not only from a theoretical perspective, but also through practical examples, helping learners connect strategic reasoning with real‑world decision‑making.
The ultimate goal is to enable learners to replicate this assessment process autonomously, apply it to the business ideas they are developing or supporting, and obtain a realistic and honest assessment of their commercial potential.
Discover the course here: https://horizoneuropencpportal.eu/academy/generating-business-research
*The NCP Academy is the training and capacity‑building platform of the Horizon Europe NCP Portal. It aims to strengthen the skills and knowledge of National Contact Points and offers online courses and learning resources across all Horizon Europe areas, with several contents also open to researchers, innovators and other potential participants.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
